Lilly Open To Providing More Guidance On Duration Of Treatment With Evista

The length of time that women take Lilly's Evista to decrease risk of invasive breast cancer is a decision to be made by patients and physicians, the company contended during a July 24 meeting of FDA's Oncologic Drugs Advisory Committee